1. Home
  2. KALA vs ORIS Comparison

KALA vs ORIS Comparison

Compare KALA & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALA
  • ORIS
  • Stock Information
  • Founded
  • KALA 2009
  • ORIS 2014
  • Country
  • KALA United States
  • ORIS China
  • Employees
  • KALA N/A
  • ORIS N/A
  • Industry
  • KALA Biotechnology: Pharmaceutical Preparations
  • ORIS Farming/Seeds/Milling
  • Sector
  • KALA Health Care
  • ORIS Consumer Staples
  • Exchange
  • KALA Nasdaq
  • ORIS Nasdaq
  • Market Cap
  • KALA 5.1M
  • ORIS 5.3M
  • IPO Year
  • KALA 2017
  • ORIS 2024
  • Fundamental
  • Price
  • KALA $0.89
  • ORIS $0.12
  • Analyst Decision
  • KALA Buy
  • ORIS
  • Analyst Count
  • KALA 3
  • ORIS 0
  • Target Price
  • KALA $31.50
  • ORIS N/A
  • AVG Volume (30 Days)
  • KALA 1.6M
  • ORIS 16.0M
  • Earning Date
  • KALA 11-19-2025
  • ORIS 01-01-0001
  • Dividend Yield
  • KALA N/A
  • ORIS N/A
  • EPS Growth
  • KALA N/A
  • ORIS N/A
  • EPS
  • KALA N/A
  • ORIS 0.00
  • Revenue
  • KALA N/A
  • ORIS $12,317,000.00
  • Revenue This Year
  • KALA N/A
  • ORIS N/A
  • Revenue Next Year
  • KALA N/A
  • ORIS N/A
  • P/E Ratio
  • KALA N/A
  • ORIS $555.16
  • Revenue Growth
  • KALA N/A
  • ORIS N/A
  • 52 Week Low
  • KALA $0.61
  • ORIS $0.08
  • 52 Week High
  • KALA $20.60
  • ORIS $56.01
  • Technical
  • Relative Strength Index (RSI)
  • KALA 39.51
  • ORIS 43.97
  • Support Level
  • KALA $0.61
  • ORIS $0.11
  • Resistance Level
  • KALA $0.70
  • ORIS $0.13
  • Average True Range (ATR)
  • KALA 0.09
  • ORIS 0.01
  • MACD
  • KALA 0.25
  • ORIS 0.00
  • Stochastic Oscillator
  • KALA 70.38
  • ORIS 37.88

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About ORIS Oriental Rise Holdings Limited Ordinary Shares

Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).

Share on Social Networks: